DMD: Which Steroid Regimen Is Best?

Trial sites have begun opening in a large study to determine which regimen of corticosteroid treatment provides maximum benefit in Duchenne muscular dystrophy

Corticosteroids like prednisone and deflazacort are in widespread use to treat Duchenne muscular dystrophy, but questions about the details remain.
Article Highlights:
  • Investigators will study 300 young boys with Duchenne MD in a five-year, phase 3 international trial comparing three treatment regimens of the corticosteroids prednisone and deflazacort.
  • The trial will explore unanswered questions about corticosteroid therapy for DMD; children will be followed for five years and will take a corticosteroid drug for three to five years.
  • Four of 40 sites are open so far, with more to follow.
by Margaret Wahl on February 15, 2013 - 3:49pm

Update (June 25, 2014): An approximately five-minute video about this FOR-DMD trial has been posted to YouTube.

Update (March 12, 2014): An approximately one-hour webinar that explains the Finding the Optimum [Corticosteroid] Regimen for Duchenne Muscular Dystrophy (FOR-DMD) trial has been posted to YouTube.

Update (Oct. 31, 2013): This story was updated to reflect that MDA is making travel support available to North American participants in this study. In addition, several additional trial sites have opened since this story was posted originally. See Finding the Optimum Regimen for DMD for regularly updated information.

original story:

Prednisone and other drugs in the corticosteroid family have become standard treatment for Duchenne muscular dystrophy (DMD) in much of the world for almost a decade. In this disorder, they slow the decline of muscle function and prolong walking ability. However, corticosteroids have significant side effects, such as weight gain, bone loss, cataracts and behavior changes.

Many questions about corticosteroid use in DMD remain, particularly about which medication, which dosage regimen, and what duration of treatment should be prescribed to maximize benefit and minimize harmful effects.

Now, with the support of the National Institute of Neurological Disorders and Stroke (NINDS), the first four sites in a 40-center, multinational trial exploring these questions have begun enrolling participants. More centers will open as they are ready.

300 boys on three regimens

In the phase 3 trial, investigators at medical centers in the United States, Canada, the United Kingdom, Germany and Italy will study young boys with DMD for five years.

Each participant will be assigned to receive one of three corticosteroid regimens for three to five years:

  • daily prednisone at 0.75 milligrams per kilogram of body weight;
  • intermittent prednisone — alternating 10 days on and 10 days off — at 0.75 milligrams per kilogram of body weight; or
  • daily deflazacort at 0.9 milligrams per kilogram of body weight.

Prospective participants must:

  • be male and have a confirmed diagnosis of DMD;
  • be 4 to 7 years old;
  • be able to rise from the floor independently; and
  • be willing and able to comply with scheduled visits, drug administration plans and study procedures, including being able to maintain reproducible respiratory measurements.

Prospective participants must not:

  • be undergoing or have had previous treatment with more than four consecutive weeks of oral corticosteroid therapy or other immunosuppressive medications;
  • have a history of major kidney or liver impairment, immune abnormalities or other contraindications to corticosteroid therapy;
  • have a history of chronic systemic fungal or viral infections;
  • have diabetes;
  • lack immunity to chickenpox;
  • have symptomatic cardiac abnormalities;
  • have severe behavioral problems;
  • weigh less than 13 kilograms (about 29 pounds); or
  • have any previous or current medical condition, physical findings or laboratory abnormalities that could affect a child's safety, make it unlikely that treatment will be completed, or impair the assessment of study results, in the judgment of the site investigator.

The principal investigators are neurologist Robert Griggs at the University of Rochester Medical Center in New York and geneticist Kate Bushby at the Institute of Human Genetics in Newcastle Upon Tyne in the United Kingdom.

To participate

For details, including contact information and recruitment status (open or not yet open) for the study sites, see Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR-DMD) (or enter NCT01603407 in the search box at

For general information about U.S. sites, contact Kimberly Hart, U.S. project manager for FOR-DMD in Rochester, N.Y., at (585) 275-3767 or MDA is making travel support available to North American participants.

The four sites that are currently open to recruitment are in Los Angeles; Rochester, N.Y.; Calgary, Alberta, Canada; and Newcastle Upon Tyne, United Kingdom.

Site-specific study coordinators at open sites follow.

Angel Hu
University of California,Los Angeles
Los Angeles
(858) 228-0461

New York
Debra Guntrum
University of Rochester Medical Center
(585) 275-6374

Caitlin Wright
Alberta Children's Hospital
Calgary, Alberta
(403) 955-3192

United Kingdom
Becky Davis
Institute of Human Genetics
International Centre for Life
Newcastle Upon Tyne
0191 241 8649

For more information

To learn more about corticosteroids and DMD, see:

Your rating: None Average: 3 (1 vote)
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email See comment policy